SEC Form 4 · accession 0001127602-17-026989
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R Meyers
Officer — EVP Worldwide Commercial Ops
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2017 | M | 60,000 | $21.00 | A | 62,715 | D | |
| Common StockF2 | Aug 31, 2017 | S | 43,300 | $83.0142 | D | 19,415 | D | |
| Common StockF3 | Aug 31, 2017 | S | 16,700 | $83.6392 | D | 2,715 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F1 | $21.00 | Aug 31, 2017 | M | 60,000 | D | — | Oct 22, 2017 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F2Sale prices reported for the transactions reported here range from $82.50 to $83.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F3Sale prices reported for the transactions reported here range from $83.51 to $83.91. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.